Dr. Yizhou Jiang 江一舟
Chief Physician, Research Professor
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of breast cancer, especially triple-negative breast cancer, and benign breast tumors. Provides precision medicine consulting, gene testing advice, Fudan University subtyping consultation, and information on new drug clinical trials.
Chief Physician and Researcher with a medical doctorate from Fudan University, trained under Professor Sha Zhimin. Specialized in breast surgery since 2011, with visiting research at Princeton University (2015-2016). Focuses on triple-negative breast cancer subtyping and precision treatment. Published over 30 SCI papers, including in Cancer Cell.
Professional roles
- Youth Committee Member, Breast Tumor Group, Oncology Branch, Chinese Medical Association
- Council Member, Youth Council, China Anti-Cancer Association
- Standing Committee Member, Tumor Targeted Therapy Professional Committee, China Anti-Cancer Association
- Executive Director, Youth Council, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Jiang Yizhou). Papers usually list the name as Yizhou Jiang or Jiang Y.
Selected publications
190 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- Signal Transduct Target Ther, 2026 (senior author): Neuro-immune interactions in tumors, immune-related disorders, and infections. PubMed 42838935
- Nat Commun, 2026 (senior author): ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition. PubMed 42401578
- Cancer Lett, 2026 (senior author): Age-related B cell dysfunction at the aging-cancer nexus: from shared manifestations to therapeutic potential. PubMed 41850575
- Beijing Da Xue Xue Bao Yi Xue Ban, 2026 (senior author): [Molecular mechanisms and clinical applications of anti-angiogenic therapy in precision treatment of breast cancer]. PubMed 41978392
- Cell Rep Med, 2026 (senior author): Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. PubMed 41850242
- Proc Natl Acad Sci U S A, 2026 (senior author): Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer. PubMed 41811442
- Cell, 2026 (senior author): Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. PubMed 41650969
- Cell Discov, 2025 (senior author): Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets. PubMed 41213951
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion